上证指数: 0000.00 0.00 00.00亿元 |
深圳成指: 0000.00 0.00 00.00亿元 |
沪深300: 0000.00 0.00 00.00亿元
| 恒瑞医药(600276) 利润表 |
| 报告期 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 |
| 一、主营业务收入 | 1,197,483,048 | 598,494,571 | 1,959,660,122 | 1,387,117,063 | 900,151,179 |
| 折扣与折让 | 0 | 0 | 0 | 0 | 0 |
| 主营业务收入净额 | 1,197,483,048 | 598,494,571 | 1,959,660,122 | 1,387,117,063 | 900,151,179 |
| 主营业务成本 | 220,632,890 | 93,767,082 | 330,374,168 | 236,931,896 | 156,659,095 |
| 主营业务税金及附加 | 18,817,230 | 9,884,569 | 31,167,659 | 22,202,798 | 14,501,974 |
| 二、主营业务利润 | 958,032,928 | 494,842,921 | 1,598,118,294 | 1,127,982,369 | 728,990,110 |
| 其他业务利润 | 0 | 0 | 0 | 0 | 0 |
| 存货跌价损失 | 0 | 0 | 0 | 0 | 0 |
| 营业费用 | 491,673,514 | 226,593,560 | 798,094,913 | 535,317,502 | 374,420,889 |
| 管理费用 | 120,224,387 | 83,778,507 | 406,229,649 | 265,080,981 | 175,048,851 |
| 财务费用 | 4,582,092 | 2,426,740 | 3,901,530 | 912,665 | 197,299 |
| 三、营业利润 | 337,012,719 | 176,904,865 | 366,799,993 | 320,794,930 | 172,944,007 |
| 投资收益 | 19,999,439 | 15,254,902 | 38,847,055 | 7,726,945 | 7,726,945 |
| 补贴收入 | 0 | 0 | 0 | 0 | 0 |
| 营业外收入 | 555,299 | 161,299 | 4,616,821 | 2,660,681 | 253,475 |
| 营业外支出 | 3,116,158 | 751 | 800,083 | 169,092 | 82,333 |
| 以前年度损益调整 | 0 | 0 | 0 | 0 | 0 |
| 营业外收支净额 | -2,560,859 | 160,549 | 3,816,738 | 2,491,589 | 171,143 |
| 四、利润总额 | 255,622,614 | 102,146,773 | 511,459,509 | 341,554,405 | 187,765,136 |
| 所得税 | 58,892,866 | 25,768,884 | 92,928,469 | 84,738,152 | 31,510,580 |
| 财政返还 | 0 | 0 | 0 | 0 | 0 |
| 少数股东权益 | 4,912,305 | 2,090,018 | 5,609,752 | 7,356,973 | 2,499,168 |
| 购买日前净利润 | 0 | 0 | 0 | 0 | 0 |
| 未确认的投资损失 | 0 | 0 | 0 | 0 | 0 |
| 五、净利润 | 191,817,442 | 74,287,871 | 412,921,287 | 249,459,281 | 153,755,388 |
| 年初未分配利润 | 0 | 0 | 0 | 0 | 0 |
| 调整以前年度损益 | 0 | 0 | 0 | 0 | 0 |
| 盈余公积转入 | 0 | 0 | 0 | 0 | 0 |
| 住房周转金转入 | 0 | 0 | 0 | 0 | 0 |
| 其他转入 | 0 | 0 | 0 | 0 | 0 |
| 六、可分配利润 | 0 | 0 | 0 | 0 | 0 |
| 提取法定盈余公积 | 0 | 0 | 0 | 0 | 0 |
| 提取法定公益金 | 0 | 0 | 0 | 0 | 0 |
| 职工奖金福利 | 0 | 0 | 0 | 0 | 0 |
| 提取储备基金 | 0 | 0 | 0 | 0 | 0 |
| 提取企业发展基金 | 0 | 0 | 0 | 0 | 0 |
| 七、可供股东分配的利润 | 0 | 0 | 0 | 0 | 0 |
| 应付优先股股利 | 0 | 0 | 0 | 0 | 0 |
| 提取任意盈余公积金 | 0 | 0 | 0 | 0 | 0 |
| 应付普通股股利 | 0 | 0 | 0 | 0 | 0 |
| 转作股本的普通股股利 | 0 | 0 | 0 | 0 | 0 |
| 八、未分配利润 | 0 | 0 | 0 | 0 | 0 |
| 恒瑞医药(600276) 利润表 |
| 报告期 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 |
| 一、主营业务收入 | 401,912,737 | 1,422,456,905 | 1,039,422,066 | 670,855,674 | 333,481,132 |
| 折扣与折让 | 0 | 0 | 0 | 0 | 0 |
| 主营业务收入净额 | 401,912,737 | 1,422,456,905 | 1,039,422,066 | 670,855,674 | 333,481,132 |
| 主营业务成本 | 60,858,609 | 266,339,173 | 190,243,509 | 124,933,260 | 60,328,528 |
| 主营业务税金及附加 | 6,635,069 | 22,608,723 | 16,543,292 | 10,541,195 | 5,326,008 |
| 二、主营业务利润 | 334,419,059 | 1,133,509,008 | 832,635,265 | 535,381,218 | 267,826,596 |
| 其他业务利润 | 0 | 999,202 | 709,745 | 448,152 | 299,323 |
| 存货跌价损失 | 0 | 0 | 0 | 0 | 0 |
| 营业费用 | 152,014,999 | 562,557,966 | 400,711,864 | 260,063,127 | 126,753,652 |
| 管理费用 | 73,751,597 | 300,882,076 | 221,033,923 | 135,599,468 | 64,504,869 |
| 财务费用 | -1,202,617 | -531,892 | -1,631,295 | -109,978 | -551,875 |
| 三、营业利润 | 109,855,079 | 271,600,060 | 213,230,519 | 140,276,753 | 77,419,272 |
| 投资收益 | 200,900 | 18,150,378 | 240,476 | 251,119 | 251,119 |
| 补贴收入 | 0 | 0 | 0 | 0 | 0 |
| 营业外收入 | 77,898 | 347,688 | 341,888 | 10,000 | 10,000 |
| 营业外支出 | 38,514 | 802,773 | 721,234 | 108,340 | 0 |
| 以前年度损益调整 | 0 | 0 | 0 | 0 | 0 |
| 营业外收支净额 | 39,384 | -455,085 | -379,346 | -98,340 | 10,000 |
| 四、利润总额 | 109,566,829 | 289,295,352 | 213,091,649 | 140,429,532 | 77,680,391 |
| 所得税 | 35,533,902 | 84,392,582 | 58,596,375 | 33,851,664 | 27,584,750 |
| 财政返还 | 0 | 0 | 0 | 0 | 0 |
| 少数股东权益 | 613,995 | -1,745,027 | -1,520,211 | -939,747 | -1,187,732 |
| 购买日前净利润 | 0 | 0 | 0 | 0 | 0 |
| 未确认的投资损失 | 0 | 0 | 0 | 0 | 0 |
| 五、净利润 | 73,418,932 | 206,647,797 | 156,015,485 | 107,517,615 | 51,283,373 |
| 年初未分配利润 | 0 | 303,174,076 | 0 | 303,174,076 | 247,058,236 |
| 调整以前年度损益 | 0 | 0 | 0 | 0 | 0 |
| 盈余公积转入 | 0 | 0 | 0 | 0 | 0 |
| 住房周转金转入 | 0 | 0 | 0 | 0 | 0 |
| 其他转入 | 0 | 0 | 0 | 0 | 0 |
| 六、可分配利润 | 0 | 509,821,873 | 0 | 410,691,691 | 298,341,608 |
| 提取法定盈余公积 | 0 | 20,664,780 | 0 | 0 | 0 |
| 提取法定公益金 | 0 | 0 | 0 | 0 | 0 |
| 职工奖金福利 | 0 | 0 | 0 | 0 | 0 |
| 提取储备基金 | 0 | 0 | 0 | 0 | 0 |
| 提取企业发展基金 | 0 | 0 | 0 | 0 | 0 |
| 七、可供股东分配的利润 | 0 | 489,157,093 | 0 | 410,691,691 | 298,341,608 |
| 应付优先股股利 | 0 | 0 | 0 | 0 | 0 |
| 提取任意盈余公积金 | 0 | 0 | 0 | 0 | 0 |
| 应付普通股股利 | 0 | 56,115,840 | 0 | 56,115,840 | 0 |
| 转作股本的普通股股利 | 0 | 0 | 0 | 0 | 0 |
| 八、未分配利润 | 0 | 433,041,253 | 0 | 354,575,851 | 298,341,608 |
| 恒瑞医药(600276) 利润表 |
| 报告期 | 2005-12-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-12-31 |
| 一、主营业务收入 | 1,179,259,558 | 877,084,597 | 578,158,248 | 290,450,607 | 1,145,143,619 |
| 折扣与折让 | 0 | 0 | 0 | 0 | 0 |
| 主营业务收入净额 | 1,179,259,558 | 877,084,597 | 578,158,248 | 290,450,607 | 1,145,143,619 |
| 主营业务成本 | 229,908,675 | 149,259,335 | 97,702,302 | 39,655,715 | 286,318,825 |
| 主营业务税金及附加 | 19,184,813 | 14,684,521 | 9,674,014 | 4,936,774 | 17,554,005 |
| 二、主营业务利润 | 930,166,070 | 713,140,741 | 470,781,932 | 245,858,118 | 841,270,789 |
| 其他业务利润 | 11,315,983 | 8,088,204 | 7,439,525 | 5,579,251 | 3,725,449 |
| 存货跌价损失 | 0 | 0 | 0 | 0 | 0 |
| 营业费用 | 475,995,119 | 390,663,046 | 259,842,784 | 134,491,047 | 430,681,738 |
| 管理费用 | 239,663,385 | 155,058,300 | 103,099,856 | 53,810,191 | 226,649,367 |
| 财务费用 | -78,556 | -357,503 | -234,695 | -48,290 | 9,875,352 |
| 三、营业利润 | 225,902,105 | 175,865,102 | 115,513,511 | 63,184,420 | 177,789,782 |
| 投资收益 | 0 | 0 | 0 | 0 | 389,389 |
| 补贴收入 | 0 | 0 | 0 | 0 | 3,920,000 |
| 营业外收入 | 220,771 | 172,271 | 50,342 | 6,700 | 252,695 |
| 营业外支出 | 5,418,928 | 1,541,147 | 70,000 | 70,000 | 9,694,823 |
| 以前年度损益调整 | 0 | 0 | 0 | 0 | 0 |
| 营业外收支净额 | -5,198,157 | -1,368,876 | -19,658 | -63,300 | -9,442,128 |
| 四、利润总额 | 220,703,948 | 174,496,226 | 115,493,853 | 63,121,120 | 172,657,042 |
| 所得税 | 60,631,261 | 45,891,600 | 41,635,062 | 24,860,721 | 51,341,575 |
| 财政返还 | 0 | 0 | 0 | 0 | 0 |
| 少数股东权益 | -2,149,370 | -1,276,412 | -2,496,256 | -1,553,600 | -1,305,028 |
| 购买日前净利润 | 0 | 0 | 0 | 0 | 0 |
| 未确认的投资损失 | 0 | 0 | 0 | 0 | 0 |
| 五、净利润 | 162,222,058 | 129,881,038 | 76,355,048 | 39,813,999 | 122,620,495 |
| 年初未分配利润 | 224,410,830 | 0 | 224,410,830 | 0 | 149,899,890 |
| 调整以前年度损益 | 0 | 0 | 0 | 0 | 0 |
| 盈余公积转入 | 0 | 0 | 0 | 0 | 0 |
| 住房周转金转入 | 0 | 0 | 0 | 0 | 0 |
| 其他转入 | 0 | 0 | 0 | 0 | 1,921,744 |
| 六、可分配利润 | 386,632,887 | 0 | 300,765,877 | 0 | 274,442,129 |
| 提取法定盈余公积 | 16,222,206 | 0 | 0 | 0 | 12,262,049 |
| 提取法定公益金 | 16,222,206 | 0 | 0 | 0 | 12,262,049 |
| 职工奖金福利 | 0 | 0 | 0 | 0 | 0 |
| 提取储备基金 | 0 | 0 | 0 | 0 | 0 |
| 提取企业发展基金 | 0 | 0 | 0 | 0 | 0 |
| 七、可供股东分配的利润 | 354,188,476 | 0 | 300,765,877 | 0 | 249,918,030 |
| 应付优先股股利 | 0 | 0 | 0 | 0 | 0 |
| 提取任意盈余公积金 | 0 | 0 | 0 | 0 | 0 |
| 应付普通股股利 | 51,014,400 | 0 | 51,014,400 | 0 | 25,507,200 |
| 转作股本的普通股股利 | 0 | 0 | 0 | 0 | 0 |
| 八、未分配利润 | 303,174,076 | 0 | 249,751,477 | 0 | 224,410,830 |
| 恒瑞医药(600276) 利润表 |
| 报告期 | 2004-09-30 | 2004-06-30 | 2004-03-31 | 2003-12-31 | 2003-09-30 |
| 一、主营业务收入 | 891,788,555 | 514,577,177 | 245,112,141 | 1,050,352,312 | 760,880,018 |
| 折扣与折让 | 0 | 0 | 0 | 0 | 0 |
| 主营业务收入净额 | 891,788,555 | 514,577,177 | 245,112,141 | 1,050,352,312 | 760,880,018 |
| 主营业务成本 | 218,315,936 | 86,984,468 | 42,762,958 | 348,193,902 | 263,359,848 |
| 主营业务税金及附加 | 13,498,578 | 8,252,960 | 3,819,039 | 13,385,680 | 9,640,013 |
| 二、主营业务利润 | 659,974,042 | 419,339,748 | 198,530,144 | 688,772,729 | 487,880,157 |
| 其他业务利润 | 3,281,753 | 1,753,385 | -24,875 | 3,987,254 | 3,971,349 |
| 存货跌价损失 | 0 | 0 | 0 | 0 | 0 |
| 营业费用 | 393,559,138 | 236,052,116 | 110,047,104 | 339,859,487 | 243,235,876 |
| 管理费用 | 139,915,849 | 96,788,110 | 38,560,188 | 198,346,513 | 138,219,680 |
| 财务费用 | 7,201,738 | 5,682,106 | 2,931,679 | 16,892,325 | 12,288,200 |
| 三、营业利润 | 122,579,070 | 82,570,803 | 46,966,298 | 137,661,659 | 98,107,751 |
| 投资收益 | -401,013 | -10,104,779 | 2,643 | 2,479,023 | 42,180 |
| 补贴收入 | 0 | 0 | 0 | 13,771,045 | 311,046 |
| 营业外收入 | 251,545 | 39,948 | 13,225 | 119,802 | 352,579 |
| 营业外支出 | 4,539,239 | 1,962,695 | 909,183 | 3,336,668 | 1,632,073 |
| 以前年度损益调整 | 0 | 0 | 0 | 0 | 0 |
| 营业外收支净额 | -4,287,694 | -1,922,747 | -895,958 | -3,216,867 | -1,279,494 |
| 四、利润总额 | 117,890,363 | 70,543,276 | 46,072,984 | 150,694,861 | 97,181,482 |
| 所得税 | 24,785,445 | 17,627,339 | 15,344,109 | 58,490,050 | 37,657,241 |
| 财政返还 | 0 | 0 | 0 | 0 | 0 |
| 少数股东权益 | 2,416,233 | 1,511,517 | -220,941 | -2,315,184 | -1,957,897 |
| 购买日前净利润 | 0 | 0 | 0 | 0 | 0 |
| 未确认的投资损失 | 0 | 0 | 0 | 0 | 0 |
| 五、净利润 | 90,688,685 | 51,404,420 | 30,949,816 | 94,519,995 | 61,482,138 |
| 年初未分配利润 | 0 | 151,821,634 | 0 | 100,044,056 | 74,536,856 |
| 调整以前年度损益 | 0 | 0 | 0 | 0 | 0 |
| 盈余公积转入 | 0 | 0 | 0 | 0 | 0 |
| 住房周转金转入 | 0 | 0 | 0 | 0 | 0 |
| 其他转入 | 0 | 0 | 0 | 40,428 | 40,428 |
| 六、可分配利润 | 0 | 203,226,054 | 0 | 194,604,478 | 136,059,421 |
| 提取法定盈余公积 | 0 | 0 | 0 | 9,598,694 | 0 |
| 提取法定公益金 | 0 | 0 | 0 | 9,598,694 | 0 |
| 职工奖金福利 | 0 | 0 | 0 | 0 | 0 |
| 提取储备基金 | 0 | 0 | 0 | 0 | 0 |
| 提取企业发展基金 | 0 | 0 | 0 | 0 | 0 |
| 七、可供股东分配的利润 | 0 | 203,226,054 | 0 | 175,407,090 | 136,059,421 |
| 应付优先股股利 | 0 | 0 | 0 | 0 | 0 |
| 提取任意盈余公积金 | 0 | 0 | 0 | 0 | 0 |
| 应付普通股股利 | 0 | 25,507,200 | 0 | 25,507,200 | 0 |
| 转作股本的普通股股利 | 0 | 0 | 0 | 0 | 0 |
| 八、未分配利润 | 0 | 177,718,854 | 0 | 149,899,890 | 136,059,421 |
| 恒瑞医药(600276) 利润表 |
| 报告期 | 2003-06-30 | 2003-03-31 | 2002-12-31 | 2002-09-30 | 2002-06-30 |
| 一、主营业务收入 | 496,021,562 | 222,771,972 | 756,025,462 | 546,911,569 | 358,278,188 |
| 折扣与折让 | 0 | 0 | 0 | 0 | 0 |
| 主营业务收入净额 | 496,021,562 | 222,771,972 | 756,025,462 | 546,911,569 | 358,278,188 |
| 主营业务成本 | 183,507,722 | 73,539,420 | 278,596,637 | 224,291,534 | 157,087,522 |
| 主营业务税金及附加 | 5,820,882 | 2,488,233 | 9,282,987 | 6,911,149 | 4,397,263 |
| 二、主营业务利润 | 306,692,958 | 146,744,320 | 468,145,838 | 315,708,886 | 196,793,403 |
| 其他业务利润 | 2,981,631 | 295,134 | 2,211,627 | 975,366 | 3,543,983 |
| 存货跌价损失 | 0 | 0 | 0 | 0 | 0 |
| 营业费用 | 145,174,154 | 77,883,197 | 234,069,135 | 134,848,685 | 76,338,174 |
| 管理费用 | 97,207,811 | 31,688,337 | 117,266,104 | 84,620,383 | 54,206,579 |
| 财务费用 | 8,159,625 | 3,586,763 | 12,711,497 | 12,195,229 | 6,405,057 |
| 三、营业利润 | 59,132,998 | 33,881,158 | 106,310,729 | 85,019,955 | 63,387,575 |
| 投资收益 | 42,180 | 0 | 4,282,750 | 1,443,578 | 1,402,778 |
| 补贴收入 | 0 | 311,045 | 4,090,000 | 3,098,000 | 715,000 |
| 营业外收入 | 89,227 | 39,394 | 373,365 | 256,860 | 125,603 |
| 营业外支出 | 1,216,877 | 452,930 | 4,547,818 | 2,344,998 | 868,832 |
| 以前年度损益调整 | 0 | 0 | 0 | 0 | 0 |
| 营业外收支净额 | -1,127,651 | -413,536 | -4,174,453 | 0 | -743,228 |
| 四、利润总额 | 58,047,527 | 33,778,668 | 110,509,026 | 87,473,395 | 64,762,124 |
| 所得税 | 26,143,261 | 11,147,139 | 31,236,834 | 24,901,176 | 17,406,358 |
| 财政返还 | 0 | 0 | 0 | 0 | 0 |
| 少数股东权益 | -3,597,552 | 75,078 | 318,195 | 635,204 | 293,620 |
| 购买日前净利润 | 0 | 0 | 0 | 0 | 0 |
| 未确认的投资损失 | 0 | 0 | 0 | 0 | 0 |
| 五、净利润 | 35,501,818 | 22,556,451 | 78,953,997 | 61,937,015 | 47,062,146 |
| 年初未分配利润 | 74,536,856 | 0 | 85,010,525 | 0 | 85,010,525 |
| 调整以前年度损益 | 0 | 0 | 0 | 0 | 0 |
| 盈余公积转入 | 0 | 0 | 0 | 0 | 0 |
| 住房周转金转入 | 0 | 0 | 0 | 0 | 0 |
| 其他转入 | 0 | 0 | -4,408,525 | 0 | -4,408,525 |
| 六、可分配利润 | 110,038,674 | 0 | 159,555,997 | 0 | 127,664,146 |
| 提取法定盈余公积 | 0 | 0 | 8,499,971 | 0 | 0 |
| 提取法定公益金 | 0 | 0 | 8,499,971 | 0 | 0 |
| 职工奖金福利 | 0 | 0 | 0 | 0 | 0 |
| 提取储备基金 | 0 | 0 | 0 | 0 | 0 |
| 提取企业发展基金 | 0 | 0 | 0 | 0 | 0 |
| 七、可供股东分配的利润 | 110,038,674 | 0 | 142,556,056 | 0 | 127,664,146 |
| 应付优先股股利 | 0 | 0 | 0 | 0 | 0 |
| 提取任意盈余公积金 | 0 | 0 | 0 | 0 | 0 |
| 应付普通股股利 | 0 | 0 | 25,507,200 | 0 | 0 |
| 转作股本的普通股股利 | 0 | 0 | 42,512,000 | 0 | 42,512,000 |
| 八、未分配利润 | 110,038,674 | 0 | 74,536,856 | 0 | 85,152,146 |
| 恒瑞医药(600276) 利润表 |
| 报告期 | 2002-03-31 | 2001-12-31 | 2001-06-30 | 2000-12-31 | 2000-06-30 |
| 一、主营业务收入 | 148,300,121 | 634,268,948 | 299,570,386 | 484,707,192 | 230,820,967 |
| 折扣与折让 | 0 | 0 | 0 | 0 | 0 |
| 主营业务收入净额 | 148,300,121 | 634,268,948 | 299,570,386 | 484,707,192 | 230,820,967 |
| 主营业务成本 | 62,544,016 | 255,391,928 | 129,735,159 | 226,709,347 | 111,515,226 |
| 主营业务税金及附加 | 1,802,392 | 7,807,360 | 3,528,244 | 4,994,224 | 2,233,993 |
| 二、主营业务利润 | 83,953,714 | 371,069,660 | 166,306,984 | 253,003,621 | 117,071,749 |
| 其他业务利润 | 204,194 | 3,253,309 | 1,187,830 | 4,054,610 | 1,061,106 |
| 存货跌价损失 | 0 | 0 | 0 | 62,130 | -116,082 |
| 营业费用 | 35,122,892 | 168,590,037 | 59,824,042 | 111,794,602 | 42,473,797 |
| 管理费用 | 26,267,750 | 107,043,998 | 45,500,298 | 65,038,218 | 31,457,631 |
| 财务费用 | 4,712,352 | 10,713,573 | 5,506,580 | 5,945,790 | 4,890,903 |
| 三、营业利润 | 18,054,914 | 87,975,361 | 56,663,894 | 74,217,491 | 39,426,605 |
| 投资收益 | 1,402,778 | 3,254,434 | 1,617,766 | -865,936 | 240,000 |
| 补贴收入 | 0 | 1,064,639 | 3,018,419 | 2,117,458 | 0 |
| 营业外收入 | 133,290 | 8,395,417 | 4,166,079 | 8,809,889 | 135,145 |
| 营业外支出 | 327,708 | 3,024,390 | 1,820,912 | 2,391,685 | 1,178,046 |
| 以前年度损益调整 | 0 | 0 | 0 | 0 | 0 |
| 营业外收支净额 | 0 | 5,371,027 | 0 | 0 | 0 |
| 四、利润总额 | 19,263,275 | 97,665,461 | 63,645,246 | 81,887,217 | 38,623,704 |
| 所得税 | 967,064 | 16,261,563 | 20,482,136 | 16,349,680 | 12,913,744 |
| 财政返还 | 0 | 0 | 0 | 0 | 0 |
| 少数股东权益 | 72,908 | 248,817 | 318,369 | 266,151 | 153,014 |
| 购买日前净利润 | 0 | 0 | 0 | 0 | 0 |
| 未确认的投资损失 | 0 | 0 | 0 | 0 | 0 |
| 五、净利润 | 18,223,303 | 81,155,081 | 42,844,740 | 65,271,386 | 25,556,946 |
| 年初未分配利润 | 0 | 64,945,002 | 64,945,002 | 27,024,265 | 35,647,281 |
| 调整以前年度损益 | 0 | 0 | 0 | 0 | 0 |
| 盈余公积转入 | 0 | 0 | 0 | 0 | 0 |
| 住房周转金转入 | 0 | 0 | 0 | 0 | 0 |
| 其他转入 | 0 | 6,595,864 | 0 | 0 | 0 |
| 六、可分配利润 | 0 | 152,695,947 | 107,789,742 | 92,295,651 | 61,204,227 |
| 提取法定盈余公积 | 0 | 8,601,211 | 0 | 7,032,825 | 0 |
| 提取法定公益金 | 0 | 8,601,211 | 0 | 7,032,825 | 0 |
| 职工奖金福利 | 0 | 0 | 0 | 0 | 0 |
| 提取储备基金 | 0 | 0 | 0 | 0 | 0 |
| 提取企业发展基金 | 0 | 0 | 0 | 0 | 0 |
| 七、可供股东分配的利润 | 0 | 135,493,525 | 107,789,742 | 78,230,002 | 61,204,227 |
| 应付优先股股利 | 0 | 0 | 0 | 0 | 0 |
| 提取任意盈余公积金 | 0 | 0 | 0 | 0 | 0 |
| 应付普通股股利 | 0 | 10,628,000 | 0 | 13,285,000 | 0 |
| 转作股本的普通股股利 | 0 | 39,855,000 | 39,855,000 | 0 | 0 |
| 八、未分配利润 | 0 | 85,010,525 | 67,934,742 | 64,945,002 | 61,204,227 |
| 恒瑞医药(600276) 利润表 |
| 报告期 | 1999-12-31 | 1998-12-31 | 1997-12-31 |
| 一、主营业务收入 | 413,929,931 | 363,792,259 | 303,570,800 |
| 折扣与折让 | 0 | 0 | 0 |
| 主营业务收入净额 | 413,929,931 | 363,792,259 | 303,570,800 |
| 主营业务成本 | 216,243,934 | 205,612,929 | 180,388,983 |
| 主营业务税金及附加 | 4,173,787 | 3,122,826 | 2,314,563 |
| 二、主营业务利润 | 193,512,210 | 155,056,505 | 120,867,253 |
| 其他业务利润 | 533,048 | 958,473 | 1,212,368 |
| 存货跌价损失 | 317,800 | 415,000 | 365,000 |
| 营业费用 | 66,931,169 | 55,584,321 | 47,032,674 |
| 管理费用 | 57,801,714 | 41,806,944 | 32,179,754 |
| 财务费用 | 6,737,560 | 9,268,138 | 10,065,806 |
| 三、营业利润 | 62,257,015 | 48,940,575 | 32,436,387 |
| 投资收益 | 303,750 | 35,363 | 81,013 |
| 补贴收入 | 1,072,516 | 3,774,010 | 12,593,727 |
| 营业外收入 | 840,953 | 555,784 | 432,572 |
| 营业外支出 | 1,763,245 | 1,171,870 | 1,032,161 |
| 以前年度损益调整 | 0 | 0 | 0 |
| 营业外收支净额 | 0 | 0 | 0 |
| 四、利润总额 | 62,710,989 | 52,133,862 | 44,511,539 |
| 所得税 | 11,061,314 | 8,494,264 | 3,382,402 |
| 财政返还 | 0 | 0 | 0 |
| 少数股东权益 | 317,207 | 409,629 | 58,459 |
| 购买日前净利润 | 0 | 0 | 0 |
| 未确认的投资损失 | 0 | 0 | 0 |
| 五、净利润 | 51,332,468 | 43,229,968 | 41,070,678 |
| 年初未分配利润 | 57,377,195 | 24,349,812 | 0 |
| 调整以前年度损益 | 0 | 0 | 0 |
| 盈余公积转入 | 0 | 0 | 0 |
| 住房周转金转入 | 0 | 0 | 0 |
| 其他转入 | 0 | 0 | 0 |
| 六、可分配利润 | 108,709,663 | 67,579,780 | 30,714,944 |
| 提取法定盈余公积 | 5,735,941 | 5,101,293 | 3,182,566 |
| 提取法定公益金 | 5,735,941 | 5,101,293 | 3,182,566 |
| 职工奖金福利 | 0 | 0 | 0 |
| 提取储备基金 | 0 | 0 | 0 |
| 提取企业发展基金 | 0 | 0 | 0 |
| 七、可供股东分配的利润 | 97,237,781 | 57,377,195 | 24,349,812 |
| 应付优先股股利 | 0 | 0 | 0 |
| 提取任意盈余公积金 | 0 | 0 | 0 |
| 应付普通股股利 | 30,640,500 | 0 | 0 |
| 转作股本的普通股股利 | 30,950,000 | 0 | 0 |
| 八、未分配利润 | 35,647,281 | 57,377,195 | 24,349,812 |